Trial Outcomes & Findings for KET-RO Plus RO DBT for Treatment Resistant Depression (NCT NCT06138691)

NCT ID: NCT06138691

Last Updated: 2026-03-30

Results Overview

Decrease in depressive symptoms as assessed via the Montgomery and Asberg Depression Rating Scale (MADRS), a clinician-interviewed assessment of depressive symtpoms. Scale ranges from 0-60 with higher scores indicating higher depression severity.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

16 participants

Primary outcome timeframe

Approximately 5 months

Results posted on

2026-03-30

Participant Flow

16 participants were consented and enrolled. However, 3 participants were deemed ineligible at the baseline assessment and did not start treatment.

Participant milestones

Participant milestones
Measure
Ketamine + RO DBT
All participants completed 4 weeks of twice weekly ketamine infusions and approximately 4 months of twice weekly RO DBT (individual and skills group/class) concurrently.
Overall Study
STARTED
13
Overall Study
COMPLETED
7
Overall Study
NOT COMPLETED
6

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

3 participants were ineligible at baseline and did not start therapy.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Ketamine + RO DBT
n=13 Participants
All participants completed 4 weeks of RO DBT and approximately 4 months of RO DBT concurrently.
Age, Continuous
29.32 age in years
STANDARD_DEVIATION 12.47 • n=4 Participants
Sex: Female, Male
Female
8 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Sex: Female, Male
Male
5 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
Asian
2 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
Black or African American
1 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
White
10 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
More than one race
0 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=4 Participants • 3 participants were ineligible at baseline and did not start therapy.
Region of Enrollment
United States
13 Participants
n=4 Participants
MADRS
26.15 score on MADRS
STANDARD_DEVIATION 5.61 • n=4 Participants

PRIMARY outcome

Timeframe: Approximately 5 months

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

Decrease in depressive symptoms as assessed via the Montgomery and Asberg Depression Rating Scale (MADRS), a clinician-interviewed assessment of depressive symtpoms. Scale ranges from 0-60 with higher scores indicating higher depression severity.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Decrease in Depressive Symptoms
12.13 Score on MADRS
Standard Deviation 8.69

SECONDARY outcome

Timeframe: Completed immediately following individual ketamine sessions during 4 weeks of ketamine-assisted RO DBT

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

Visual analogue sliding scale (0-100) of self-reported ratings of feeling "depressed" or "anxious" in the moment, with higher scores indicating higher depression or anxiety. This visual analogue scale was administered three times: pre-ketamine, 40 minutes post-ketamine and 90 minutes post-ketamine. Reported below is the average rating across all ketamine sessions across the 4 weeks at the 90 minute post-ketamine reported. Units of measure are on the 0 to 100 scale.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Visual Analogue Scale (VAS) of Depressive and Anxiety Symptoms
Average anxiety rating 90-minutes post-ketamine infusion
22.94 units on a scale
Standard Deviation 14.97
Visual Analogue Scale (VAS) of Depressive and Anxiety Symptoms
Average depression rating 90-minutes post-ketamine infusion
23.69 units on a scale
Standard Deviation 18.65

SECONDARY outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

The Reward Positivity (RewP) is an electroencephalogram (EEG) based event related potential (ERP) and neural marker of reward responding. During the "Doors Task", a commonly used task to elicit the RewP, participants can win money or lose money when opening doors. The RewP is calculated as the electrical signal in response to winning at electrode Cz on the scalp minus the electrical signal in response to losing at electrode Cz between the timepoints 250-500ms. Thus, it is a difference score of win minus loss response to assess reward response and is measured via microvolts with higher scores indicating a stronger neural response to reward. It will examine change mid-treatment (Post Ketamine) and post treatment. Post-treatment RewP scores reported below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Reward Positivity (RewP)
0.58 uV (microvolts) from EEG
Standard Deviation 4.17

SECONDARY outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

The erorr-related negativity (ERN) is an electroencephalogram (EEG) based neural marker of error monitoring measured via an event related potential (ERP). It is elicited via Go/No-go tasks where participants make 'correct' responses and 'error' responses. The ERN is calculated as the electrical signal in response to making an error response at Cz on the scalp minus the electrical signal in response to making a correct response at electrode Cz between timepoints 0-50ms. Thus, it is a difference score of error - correct neurla response to assess error or performance monitoring and is measured via microvolts with higher scores indicating a larger response to errors. It will examine change mid-treatment (post ketamine) and post-treatment. Post-treatment ERN scores reported below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Error-related Negativity (ERN)
0.00 uV (microvolts) in EEG signal
Standard Deviation 5.20

SECONDARY outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

The Social Connectedness Scale Revised (SCS-R) is a self-report that assesses interpersonal closeness with a range of scores from 20 to 120, with a higher total score indicating greater social connectedness. This measure will examine mechanistic change mid-treatment (post ketamine) and post-treatment; Post-treatment scores provided below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Social Connectedness Scale- Revised (SCS-R)
81.00 units on a scaale
Standard Deviation 16.61

SECONDARY outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

The UCLA loneliness scale measure social connectedness (or lack of given it assesses perceived loneliness) via self-report with a range of 20 to 80 with higher scores indicating greater loneliness. This measure will examine mechanistic change mid-treatment (post ketamine) and post-treatment; Post-treatment scores provided below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
UCLA Loneliness Scale
34.38 units on a scaale
Standard Deviation 5.60

OTHER_PRE_SPECIFIED outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

The Temporal Experience of Pleasure Scale (TEPS) is a self-report behavioral assessment. This measure assesses anticipatory pleasure and consummatory or outcome pleasure of reward responding into a total score of reward responding, with scores ranging from 18 to 108 with higher scores indicating greater capacity for pleasure and reward. It will examine mechanistic change mid-treatment (post ketamine) and post-treatment; post-treatment scores reported below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Temporal Experience of Pleasure Scale (TEPS)
39.88 units on a scale
Standard Deviation 8.66

OTHER_PRE_SPECIFIED outcome

Timeframe: Immediately post-treatment (approximately 5 months since baseline)

Population: 16 participants consented to the study. However, 3 were ineligible at baseline and so did not complete any ketamine or RO DBT treatment.

The Acceptanc and Action Qustionnaire-II (AAQ-II) is a self-reported beahvioral measure of psychological inflexibility with scores ranging from 7 to 49, with higher scores indicating greater psychological inflexibility. It will examine mechanistic change mid-treatment (post-ketamine) and post-treatment; post-treatment scores provided below.

Outcome measures

Outcome measures
Measure
Ketamine and RO DBT
n=13 Participants
All participants completed 4 weeks of ketamine (twice weekly infusions) and approximately 4 months of RO DBT (twice weekly: 1 individual session and 1 skills class/group session). The 4 weeks of ketamine occurred at the same time as RO DBT therapy and then RO DBT therapy continued another approximately 3 months.
Acceptance and Action Questionnaire--II (AAQ-II)
27.63 units on a scale
Standard Deviation 4.34

Adverse Events

Ketamine + RO DBT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Kirsten Gilbert, PhD

Washington University in St. Louis

Phone: 314-747-0001

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place